---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-23-008068"
form_type: "8-K"
ticker: "BGLC"
cik: "0001737523"
company_name: "BioNexus Gene Lab Corp"
filed_at: "2023-11-03T23:59:59+00:00"
generated_at: "2026-06-08T22:38:04.583808+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BioNexus Gene Lab CFO Wei Li Leong resigns effective Oct 30, 2023

## Summary
- Wei Li Leong resigned as CFO effective October 30, 2023; will stay for one additional month.
- Resignation not due to any disagreement with the company, management, or board.
- Company to actively identify a replacement CFO; no successor named as of Nov 3, 2023.

## SEC filing metadata
- accession: 0001477932-23-008068
- form_type: 8-K
- ticker: BGLC
- cik: 0001737523
- company_name: BioNexus Gene Lab Corp
- filed_at: 2023-11-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737523/000147793223008068/0001477932-23-008068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737523/000147793223008068/bglc_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-23-008068
- JSON: https://secwatch.observer/filing/0001477932-23-008068.json
- Plain text: https://secwatch.observer/filing/0001477932-23-008068.txt

## Key facts
- Executive change
  Wei Li Leong resigned as Chief Financial Officer at BioNexus Gene Lab Corp.
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On October 30, 2023, Ms. Wei Li Leong, the Chief Financial Officer (“CFO”), tendered her resignation letter to BioNexus Gene Lab Corp. (the “Company”) from her position at the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737523/000147793223008068/0001477932-23-008068-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.